Antonio Marangoni

Ferrara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Journal: Annals of the rheumatic diseases

Published: January 30, 2026

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.

Journal: RMD open

Published: October 08, 2025

Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosus.

Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosus.

Journal: Scientific reports

Published: March 07, 2025

Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study.

Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study.

Journal: Lupus science & medicine

Published: December 24, 2024

Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.

Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.

Journal: RMD open

Published: October 11, 2024

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.

Journal: Annals of the rheumatic diseases

Published: August 25, 2023

Optimizing Patient Care: A Systematic Review of Multidisciplinary Approaches for SLE Management.

Optimizing Patient Care: A Systematic Review of Multidisciplinary Approaches for SLE Management.

Journal: Journal of clinical medicine

Published: May 08, 2023

Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Correction to: Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Journal: Clinical rheumatology

Published: October 20, 2022

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).

Journal: Clinical rheumatology

Published: July 06, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026